Scotiabank initiated coverage of Johnson & Johnson with an Outperform rating and $230 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- enGene price target raised to $10 from $4 at UBS
- FDA appoints Richard Pazdur as Director of CDER
- Halozyme: JNJ gets FDA approval for new indication of DARZALEX Faspro
- Johnson & Johnson announces FDA approval of DARZALEX FASPRO for HR-SMM
- FDA approves J&J’s Darzalex Faspro for high-risk smoldering multiple myeloma